Omid Hamid MD
Chief of Research and Immunotherapy • ImmunoOncology • Phase I Clinical Trials • Melanoma • Cutaneous Oncology
Last synced from Twitter 90d ago
The McGRAW Trial | Parker Institute for Cancer Immunotherapy
Can altering the gut microbiome improve patient response to cancer immunotherapy?
Pfizer, BioNTech COVID-19 Vaccine Planned for Late November FDA Submission
Pfizer anticipates to have completed FDA-mandated safety data a month from now. An EUA application should shortly follow.
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
Neoadjuvant immunotherapy combination in the NABUCCO trial elicits high pathological complete response rates in patients with locoregionally advanced (stage III) urothelial cancer and provides molecular biomarkers of treatment efficacy.
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma
Neoadjuvant combination of immune checkpoint therapy in patients with cisplatin-ineligible bladder cancer achieves clinical efficacy and uncovers immune features as potential predictive biomarkers of treatment response.
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer
In a phase Ib clinical trial, Ott et al. demonstrate feasibility, safety, and immunogenicity
of the combination of personalized neoantigen vaccines and PD-1 inhibition in patients
with advanced solid tumors. Vaccine-induced T cells persist over...
Microbiota-modulated CART+ enteric neurons autonomously regulate blood glucose
The gut is a stretchy, glandular, and highly innervated tube packed at its distal end with microorganisms. Disruption of the microbial community can lead to metabolic disorders such as obesity and diabetes. Muller et al. investigated how the...
COVID-19 Outbreak and Enrollment in Cancer Clinical Trials
This cohort study investigates how the coronavirus disease 2019 (COVID-19) pandemic is associated with national enrollment in cancer clinical trials.
Gutierrez Provides Insight on Bridging Gaps in Cancer Care
In our exclusive interview, Rodolfo Gutierrez, MD, discusses the issues that surround access to care and clinical outcomes with Hispanic patients, efforts The Angeles Clinic has spearheaded to bridge this gap in care, and the importance of patient...
Omid Hamid MD
Dr. Gutierrez, my colleague, discussing #disparities in care for #Hispanic #latino patients. @OncLive @angelesclinic
105d
Areas of unmet needs in melanoma
Michael Postow, MD, Memorial Sloan Kettering Cancer Center, New York, NY, outlines areas of unmet needs in melanoma. These include...
Call for Code Awards Announcement - IBM Developer
Watch live at 7:30 pm ET on October 13 as the 2020 Call for Code Global Challenge winner is revealed.
Immunotherapies could target aggressive pancreatic cancer, research indicates
Scientists have discovered that hard-to-treat pancreatic cancer hijacks a key immune system response
Melanoma in situ: Imaging technique improves margin mapping
Performing reflectance confocal microscopy (RCM) with a mosaic technique before surgery can improve margin mapping in melanoma in situ (MIS), according to a recent study presented at 2020 ASDS Virtual Annual Meeting.
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial
The randomized phase 2 trial S1320 comparing different dosing schedules of BRAF/MEK inhibitor combination in BRAF-mutated advanced melanoma shows intermittent therapy does not result in superior progression-free survival in patients.
Sami Anwar raked in millions of dollars gathering drug trial data at his sites. But it was all a lie — and now he's been sentenced to 28 years
According to federal prosecutors, Sami Anwar was quite successful in reaping millions of dollars operating trial sites in Washington state for drug developers. He offered safety data on dozens of drugs covering a gamut of ailments — from diabetes,...
Omid Hamid MD
Thanks @endpts
As if #clinicaltrials weren't hard enough this article will be shown to me by every patient from here to eternity
106d
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
Clinical activity and biomarker analysis from the COMBI-i trial evaluating PD-1, BRAF and MEK inhibition in patients with metastatic melanoma demonstrate high response rates and uncover molecular correlates of long-term treatment benefit.
Animated Patient Videos | Melanoma Research Foundation
We are excited to provide the MRF's new online patient education resource, You and Melanoma: An Animated Patient's Guide to Melanoma.
Conference
Omid Hamid MD
are you on the @ACureInSight1 Ocular Melanoma meeting - going on now
event.socialiconagency.com/e/acis-survivo… pic.twitter.com/DcvDC58Ddh
108d